Free Trial
The Rate Lock Ends Tonight! MarketBeat All Access Returns to $249
  • 0Days
  • 0Hours
  • 0Minutes
  • 0Seconds
Save $100 a Year
Claim MarketBeat All Access Sale Promotion

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$23.25
+2.6%		$23.14
$19.40
▼
$27.98
$11.32B1.74.85 million shs3.49 million shs
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
$19.23
-0.5%		$19.25
$14.68
▼
$24.68
$2.04B0.382.92 million shs1.19 million shs
The 7 Best High-Yield Dividend Stocks for 2027 Cover
The 7 Best High-Yield Dividend Stocks for 2027

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
+2.74%+2.48%+2.94%-12.02%+2.93%
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
-0.47%+5.78%+3.17%+29.41%-18.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$23.25
+2.6%		$23.14
$19.40
▼
$27.98
$11.32B1.74.85 million shs3.49 million shs
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
$19.23
-0.5%		$19.25
$14.68
▼
$24.68
$2.04B0.382.92 million shs1.19 million shs
The 7 Best High-Yield Dividend Stocks for 2027 Cover
The 7 Best High-Yield Dividend Stocks for 2027

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
+2.74%+2.48%+2.94%-12.02%+2.93%
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
-0.47%+5.78%+3.17%+29.41%-18.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
2.71
Moderate Buy$29.3326.18% Upside
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
2.00
Hold$22.8818.95% Upside

Current Analyst Ratings Breakdown

Latest SRPT and ELAN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/29/2026
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access to unlock brokerage rankings
Lower Price TargetEqual Weight$26.00 ➝ $25.00
10/28/2026
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
DowngradeSell (D-) ➝ Sell (E+)
10/20/2026
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
Jefferies Financial Group Inc. logo
Jefferies Financial Group
Subscribe to MarketBeat All Access to unlock brokerage rankings
DowngradeBuy ➝ Hold$31.00 ➝ $24.00
10/16/2026
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
The Goldman Sachs Group, Inc. logo
The Goldman Sachs Group
Subscribe to MarketBeat All Access to unlock brokerage rankings
Initiated CoverageBuy$32.00
10/13/2026
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeSell (E+) ➝ Sell (D-)
10/8/2026
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access to unlock brokerage rankings
Lower Price TargetSector Perform$19.00 ➝ $17.00
10/5/2026
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access to unlock brokerage rankings
DowngradeHold ➝ Strong Sell
10/5/2026
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingSell$5.00
9/30/2026
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
KeyCorp logo
KeyCorp
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingOverweight
9/30/2026
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access to unlock brokerage rankings
Lower Price TargetNeutral$23.00 ➝ $20.00
9/28/2026
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
Needham & Company LLC logo
Needham & Company LLC
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingUnderperform
(Data available from 10/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$4.72B2.46$2.38 per share9.76$13.18 per share1.76
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
$2.20B0.92N/AN/A$10.89 per share1.77
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
-$232M-$0.41N/A18.162.01-3.96%8.13%3.99%11/6/2026 (Estimated)
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
-$713.41M-$2.90N/A14.350.35-13.48%-1.60%-0.66%11/5/2026 (Confirmed)

Latest SRPT and ELAN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/6/2026Q3 2026
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$0.2028N/AN/AN/A$1.21 billionN/A
11/5/2026Q3 2026
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
$0.0740N/AN/AN/A$352.20 millionN/A
8/5/2026Q2 2026
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$0.2692$0.34+$0.0708$0.11$1.31 billion$1.37 billion
8/5/2026Q2 2026
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
$0.2173$0.64+$0.4227-$0.05$366.39 million$401.25 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
N/AN/AN/AN/AN/A
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
0.58
2.05
1.10
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
0.55
4.42
2.62

Institutional Ownership

CompanyInstitutional Ownership
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
97.48%
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
86.68%

Insider Ownership

CompanyInsider Ownership
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
1.14%
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
6.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
9,400499.62 million493.93 millionOptionable
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
835105.63 million98.34 millionOptionable

Recent News About These Companies

Leerink keeps USD 20.00 target for Sarepta Therapeutics stock
October 29 at 2:50 PM  |  ad-hoc-news.deA
Sarepta Therapeutics (SRPT) Earnings Expected to Grow: Should You Buy?
October 29 at 11:02 AM  |  zacks.comhttps://www.zacks.com/stock/news/3018559/sarepta-therapeutics-srpt-earnings-expected-to-grow-should-you-buy?cid=cs-stocknewsapi-ft-fundamental_analysis|yseop_template_9-3018559
Sarepta Therapeutics (SRPT) Set to Announce Quarterly Earnings on Thursday
October 29 at 3:10 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/upcoming-sarepta-therapeutics-srpt-set-to-announce-quarterly-earnings-on-thursday-2026-10-29/
Sarepta Therapeutics (NASDAQ:SRPT) Share Price Crosses Above Two Hundred Day Moving Average - Should You Sell?
October 28 at 3:21 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31163141
Sarepta Therapeutics to Present at Upcoming Investor Conferences - October 26, 2026
October 26, 2026  |  biospace.comB
Sarepta Therapeutics' PD Biomarker Data From FSHD, DM1 Studies Will Be in Focus, Wedbush Says
October 26, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/sarepta-therapeutics-apos-pd-biomarker-153524823.html
Sarepta Therapeutics to Present at Upcoming Investor Conferences
October 26, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20261026409334/en/Sarepta-Therapeutics-to-Present-at-Upcoming-Investor-Conferences/
Sarepta Therapeutics (SRPT) Receives a Rating Update from a Top Analyst
October 22, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/SRPT/pressreleases/8319758/sarepta-therapeutics-srpt-receives-a-rating-update-from-a-top-analyst/
Sarepta Therapeutics to Announce Third Quarter 2026 Financial Results
October 22, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20261022410590/en/Sarepta-Therapeutics-to-Announce-Third-Quarter-2026-Financial-Results/
Analysts Offer Insights on Healthcare Companies: Definium Therapeutics (DFTX), Sarepta Therapeutics (SRPT) and BioNTech SE (BNTX)
October 20, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/DFTX-Q/pressreleases/8228881/
Sarepta Therapeutics (NASDAQ:SRPT) Shares Up 8.2% - Time to Buy?
October 20, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-sarepta-therapeutics-nasdaq-srpt-shares-up-82-time-to-buy-2026-10-20/
H.C. Wainwright keeps USD 5 target for Sarepta Therapeutics stock
October 20, 2026  |  ad-hoc-news.deA
Sarepta Therapeutics, Inc. (SRPT) Stock Analysis: Navigating a 26.53% Potential Upside Amidst Biotechnology Challenges
October 19, 2026  |  directorstalkinterviews.comhttps://www.directorstalkinterviews.com/sarepta-therapeutics-inc-srpt-stock-analysis-navigating-a-26-53-potential-upside-amidst-biotechnology-challenges/4121266998
Cartesian Therapeutics (NASDAQ:RNAC) and Sarepta Therapeutics (NASDAQ:SRPT) Head to Head Contrast
October 19, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31133247
Sarepta presents 80 percent DM1 data for Sarepta Therapeutics stock
October 18, 2026  |  ad-hoc-news.deA
What Is The Case For Waiting On Moderna Stock?
October 17, 2026  |  trefis.comT
Leerink Partners Reaffirms Their Hold Rating on Sarepta Therapeutics (SRPT)
October 16, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/SRPT/pressreleases/8093890/leerink-partners-reaffirms-their-hold-rating-on-sarepta-therapeutics-srpt/
Sarepta Therapeutics Faces New Growth Opportunity Emerging From SiRNA Programs, Wedbush Says
October 16, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/sarepta-therapeutics-faces-growth-opportunity-160133849.html
Sarepta Therapeutics: Buy Rating Reiterated on Expanding RNA Pipeline; Price Target Maintained at $35
October 16, 2026  |  tipranks.comhttps://www.tipranks.com/news/ratings/sarepta-therapeutics-buy-rating-reiterated-on-expanding-rna-pipeline-price-target-maintained-at-35-ratings-news?utm_source=marketbeat.com&utm_medium=referral
Sarepta Therapeutics, Inc. Presents New Preclinical Data Demonstrating Robust Knockdown Of Pathogenic DMPK RNA In The Nucleus With SRP-1003 In DM1 At 2026 Oligonucleotide ...
October 15, 2026  |  marketscreener.comM
Sarepta Therapeutics Presents New Preclinical Data Demonstrating Robust Knockdown of Pathogenic DMPK RNA in the Nucleus with SRP-1003 in DM1 at 2026 Oligonucleotide ...
October 15, 2026  |  marketscreener.comM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Elanco Animal Health stock logo

Elanco Animal Health NYSE:ELAN

$23.25 +0.60 (+2.64%)
Closing price 10/29/2026 03:59 PM Eastern
Extended Trading
$23.24 -0.01 (-0.03%)
As of 06:32 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.

Sarepta Therapeutics stock logo

Sarepta Therapeutics NASDAQ:SRPT

$19.23 -0.09 (-0.47%)
Closing price 10/29/2026 04:00 PM Eastern
Extended Trading
$18.61 -0.62 (-3.24%)
As of 05:47 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas